克隆(Java方法)
断点群集区域
免疫学
类风湿性关节炎
等离子体电池
抗体
剧目
B细胞
医学
滑液
关节炎
生物
基因
遗传学
病理
物理
声学
替代医学
骨关节炎
作者
Marieke E. Doorenspleet,P. L. Klarenbeek,Maria J. H. de Hair,Barbera D. C. van Schaik,R. E. Esveldt,Antoine H. C. van Kampen,Daniëlle M. Gerlag,Annelie H. Musters,Frank Baas,Paul P. Tak,Niek de Vries
标识
DOI:10.1136/annrheumdis-2012-202861
摘要
Objective
To identify potential autoreactive B-cell and plasma-cell clones by quantitatively analysing the complete human B-cell receptor (BCR) repertoire in synovium and peripheral blood in early and established rheumatoid arthritis (RA). Methods
The BCR repertoire was screened in synovium and blood of six patients with early RA (ERA) (<6 months) and six with established RA (ESRA) (>20 months). In two patients, the repertoires in different joints were compared. Repertoires were analysed by next-generation sequencing from mRNA, generating >10 000 BCR heavy-chain sequence reads per sample. For each clone, the degree of expansion was calculated as the percentage of the total number of reads encoding the specific clonal sequence. Clones with a frequency ≥0.5% were considered dominant. Results
Multiple dominant clones were found in inflamed synovium but hardly any in blood. Within an individual patient, the same dominant clones were detected in different joints. The majority of the synovial clones were class-switched; however, the fraction of clones that expressed IgM was higher in ESRA than ERA patients. Dominant synovial clones showed autoreactive features: in ERA in particular the clones were enriched for immunoglobulin heavy chain gene segment V4–34 (IGHV4–34) and showed longer CDR3 lengths. Dominant synovial clones that did not encode IGHV4–34 also had longer CDR3s than peripheral blood. Conclusions
In RA, the synovium forms a niche where expanded—potentially autoreactive—B cells and plasma cells reside. The inflamed target tissue, especially in the earliest phase of disease, seems to be the most promising compartment for studying autoreactive cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI